Gen AI in PV and Regulatory Affairs
Marty Boom, Global Head of Regulatory & Safety, Navitas Life Sciences
Our proposed content will explore targeted applications of Gen AI within Pharmacovigilance and regulatory affairs, highlighting its potential to streamline processes, improve decision-making, and ultimately, drive better outcomes for all stakeholders.
1. How has Generative AI impacted pharmacovigilance (PV) and regulatory affairs in the life sciences industry?
Generative AI has already started transforming many industries, and the impact on the life sciences is no different. We’ve seen use cases of how Gen AI can impact clinical trials. Similarly, we expect Gen AI to positively impact domains like Regulatory Affairs (RA) & Pharmacovigilance (PV) by optimizing workflows and helping humans focus on value added tasks thereby enhancing efficiency of the processes. This is also evident from the survey data collected from our proprietary industry networks related to Regulatory & PV (pvnet®, pvconnect®, pvtech®, & rimnet®)
Any process that involves going through multiple data sources, structured and unstructured content, large amounts of data, and summarizing & generating new content will be served by Gen AI. Additionally, content creation for training purposes is another area where Gen AI will have a significant impact.
2. What challenges has Navitas Life Sciences faced in integrating Generative AI into PV and regulatory processes, and how were they addressed?
We need to be aware of the following challenges when it comes to applying Gen AI for Regulatory & Safety processes.
- Ensuring regulatory compliance (that hasn’t necessarily kept up with the latest developments in the AI space)
- Protecting proprietary information
- Eliminating systemic bias & ensuring fairness
- Ensuring traceability of content generated
- Ensuring consistency of output
- Complying with Data privacy and security.
Navitas Life Sciences has addressed most of these challenges by incorporating human expertise to provide necessary oversight, implementing continuous learning mechanisms, ensuring robust data privacy measures, and developing adaptable AI systems to keep pace with regulatory changes. We have over 250 professionals who are experts at working with 100+ Health Authorities, and whose expertise may be leveraged to optimize the use of AI in its PV and regulatory processes, ensuring regulatory compliance, accuracy, and security.
3. How does Navitas Life Sciences ensure ethical AI use and patient privacy in leveraging AI technologies?
Navitas Life Sciences takes ethical AI use and patient privacy very seriously. These are critical to AI adoption in the life sciences industry. We use these principles right from the design stage through to the validation of the systems & processes we use. Having necessary human oversight ensures that ethical dilemmas are resolved in a conventional manner.
4. Can you share insights into how Generative AI has transformed adverse event reporting and improved patient safety or reporting accuracy?
Generative AI has a significant impact on adverse event reporting. Here are some insights into how it has transformed adverse event reporting and improved patient safety and reporting accuracy:
Enhanced Customer Interactions: Generative AI enables improved chat and search experiences for customers, enhancing interactions through platforms like Medical Information Call Center (MICC) and website intake. This ensures better understanding and faster resolution of queries related to adverse events, contributing to overall patient safety.
Efficiency and Accuracy in Safety Applications: Natural language processing (NLP) is utilized to enhance the efficiency and accuracy of safety applications. Generative AI aids in case creation from unstructured data sources, such as medical reports or patient narratives. It also assists in generating case narratives and automating follow-ups to healthcare professionals, ensuring that adverse events are reported comprehensively and promptly.
Automation of Tasks and Processes: Generative AI automates various tasks and processes within PV, saving time and resources for businesses and organizations. This includes fully automated non-serious case processing and building aggregate reports, among other tasks, streamlining the reporting process and improving overall efficiency.
Exploration of Unstructured Data: Through conversational interfaces and summarizations, Generative AI enables the exploration of vast amounts of unstructured data. This includes social monitoring, automatic coding of medical events, identification of lab results, past medication, and historical conditions. By analyzing this data, potential adverse events can be detected more accurately and promptly.
Analysis of Complex Data: Generative AI allows for the analysis of complex data from multiple sources, helping businesses and researchers uncover safety signals, hidden patterns, and trends. This enhances risk-benefit analysis by providing deeper insights into the safety profiles of drugs or medical products, ultimately improving patient safety.
Generative AI has revolutionized adverse event reporting by streamlining processes, improving accuracy, and enabling the exploration and analysis of vast amounts of data, ultimately leading to better patient safety and more informed decision-making in the life sciences industry.
5. How has Generative AI influenced regulatory submissions and approvals?
Generative AI has revolutionized regulatory submissions and approvals by automating various tasks and processes, thereby enhancing efficiency, accuracy, and compliance. Some of the use cases for Regulatory Automation are highlighted below:
- Content Authoring: Authoring of regulatory documents like CSR, Summary reports, and generation of structured data from clinical trial documents
- Clinical trial data summarization: It helps in summarizing complex clinical trial data, converting tabular data into text format, and preparing patient summary reports for each study.
- Converting protocol into Informed Consent Forms (ICF): Generative AI automates the generation of ICF based on study protocols.
- Document search and retrieval: Generative AI enables quick document retrieval based on keywords, improving efficiency during the regulatory submission process.
6. How has Generative AI improved the management and analysis of vast datasets in PV and regulatory affairs, impacting decision-making?
Generative AI has significantly enhanced the management and analysis of vast datasets in PV and regulatory affairs, leading to more informed decision-making.
In regulatory intelligence, Generative AI provides up-to-date information on evolving regulations through regulatory updates and alerts. This ensures that regulatory strategies remain compliant and adaptable to the ever-changing landscape.
In the PV domain, Gen AI helps in areas like literature monitoring & surveillance, aggregate report writing & signal detection and management. All these involve going through large amounts of data - both structured and unstructured.
7. What emerging trends or innovations in Generative AI do you believe will further revolutionize PV and regulatory affairs?
Some of the emerging trends in this space include:
Replacement of Search Engine with AI: AI approaches will replace traditional search engines, ensuring that content is served by AI algorithms tailored to specific needs.
Increased Role of Gen AI in Decision-Making: Generative AI will play a major role in decision-making processes, providing insights and recommendations based on data analysis.
Early Detection of Safety Signals: AI algorithms will detect trends in safety signals well before manual processes, enabling quicker response and intervention.
Touch-less PV Case Processing & Increased reporting of Adverse Events (AEs): There will be a move towards developing nearly touch-less PV case processing as most of the data can be created or generated by Gen AI systems or programs. Gen AI’s ability to make sense of vast amounts of unstructured data can lead to greater reporting of AE information from social media monitoring & literature monitoring.
Auto-Generation of Reports & Narrative information: Generative AI will facilitate automatic generation of reports based on underlying case data, medical knowledge, regulatory inputs, and social media feedback.
However, it is important to have a human in the loop to provide necessary oversight.
8. How should individuals and organizations adapt to meet the demands of integrating AI into pharmacovigilance and regulatory affairs?
Adopting AI is a significant change for both individuals and organizations. AI will result in greater automation & more efficient processes. This frees up human resources to be redeployed in high value-add activities. However, this is only possible if organizations and employees accept and adapt to the new environment quickly. Investments in education, change management and partnerships among various participants enable adoption of this change. Organizations should critically re-visit existing processes in RA & PV to see if AI can help perform these activities more effectively and efficiently. It´s difficult to find new team members who come “fully trained or educated” on AI. The education system is lagging behind. I do think that it offers an opportunity for my current team, but it requires individual team members to embrace AI and invest in getting themselves trained in using AI tools.
9. How do partnerships between regulatory bodies, industry, and academia foster innovation in AI applications in healthcare?
Regulatory bodies play an active role in this space, issuing guidelines for the use of AI and other innovative technologies. Additionally, there are proof-of-concepts (POCs) between industry and regulatory bodies in these areas for reviewing and approving new drug applications. Navitas Life Sciences is at the forefront in promoting AI for the life sciences industry through its industry forums and partnerships with best-in-class technology vendors in the RA & PV domains. Discussions and free exchange of information related to AI in these forums help in greater understanding and adoption, leading to innovative uses of AI to solve industry pain points.
10. What leadership principles guide promoting an innovative culture at Navitas Life Sciences amidst technological transformation?
Navitas Life Sciences invests in technology initiatives based on quality and productivity gains, focusing on timelines and efforts. We track these metrics for each tech innovation project. Additionally, besides internal productivity gains, Navitas Life Sciences looks for opportunities where our clients can directly experience the benefits of these projects.
11. How do Navitas Life Sciences’ Generative AI initiatives align with broader sustainability goals within the pharmaceutical industry?
I think the link between Generative AI and Sustainability is, in our situation, a bit more vague or less tangible. One can always say that productivity gains expected from investments in Gen AI will contribute to the sustainability goals of the industry but, like I said, this is not very tangible.
12. What advice would you offer to companies navigating the complexities of effectively integration of Gen AI into their PV and Reg strategies based on your experience?
Implementing Gen AI into PV and Reg operations can be a complex and expensive project. Organizations would do well to focus on the business cases in Regulatory & PV that can deliver value through leveraging Gen AI, rather than be carried away by the technology itself. Once a potential ROI is established, a cross-functional group comprising various stakeholders from Business, IT (& legal) can look at how to progress with these initiatives. It is essential to plan these projects progressively, with small improvements in each project phase bearing in mind that we haven´t yet got all the regulatory frameworks in place to make big steps in a safe manner. AI projects will require multi-year engagements. Many life sciences organizations have also utilized the services of external consultant organizations like Navitas Life Sciences to bring in expertise and make these initiatives more successful.
Author Bio
Marty Boom is a seasoned leader with over two decades of experience in regulatory affairs, pharmacovigilance, and management consulting within the life sciences industry. As the Global Head of Regulatory & Safety at Navitas Life Sciences, he has demonstrated expertise in integrating diverse business units, leading large teams across multiple countries, and providing strategic guidance to top pharmaceutical companies.
